Interpace Biosciences, Inc.

OTCPK:IDXG Stock Report

Market Cap: US$6.3m

Interpace Biosciences Past Earnings Performance

Past criteria checks 3/6

Interpace Biosciences has been growing earnings at an average annual rate of 42.2%, while the Healthcare industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 9.9% per year.

Key information

42.2%

Earnings growth rate

45.1%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate9.9%
Return on equityn/a
Net Margin3.1%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Interspace Biosciences trades high, appoints new finance chief

Feb 04

Interpace signs licensing agreement for monoclonal antibody platform Das-1

Feb 01

Revenue & Expenses Breakdown
Beta

How Interpace Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:IDXG Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24411201
31 Dec 23401201
30 Sep 2338-1191
30 Jun 2337-2201
31 Mar 2334-4201
31 Dec 2232-6201
30 Sep 2233-6211
30 Jun 2232-6211
31 Mar 2231-4201
31 Dec 2133-7201
30 Sep 2134-13222
30 Jun 2134-18242
31 Mar 2133-24253
31 Dec 2032-29273
30 Sep 2027-32273
30 Jun 2026-33283
31 Mar 2027-33283
31 Dec 1924-27253
30 Sep 1926-20233
30 Jun 1924-16192
31 Mar 1923-12182
31 Dec 1822-12172
30 Sep 1820-13182
30 Jun 1819-13182
31 Mar 1817-18172
31 Dec 1716-13171
30 Sep 1715-1152
30 Jun 1714-5152
31 Mar 1714-3162
31 Dec 1613-8162
30 Sep 1613-23192
30 Jun 1612-23202
31 Mar 1610-28232
31 Dec 159-31252
30 Sep 15-83-31132
30 Jun 15-57-27151
31 Mar 15-28-20150
31 Dec 141-13150
30 Sep 14123-6230
30 Jun 14129-5230
31 Mar 14135-4240
31 Dec 13147-2250
30 Sep 13150-25270
30 Jun 13148-24270

Quality Earnings: IDXG has high quality earnings.

Growing Profit Margin: IDXG became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IDXG has become profitable over the past 5 years, growing earnings by 42.2% per year.

Accelerating Growth: IDXG has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: IDXG has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (14.9%).


Return on Equity

High ROE: IDXG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.